LinkOPH

Patients infected with HIV have a four-fold increased risk for developing intermediate stage age-related macular degeneration compared with same-aged people who are not infected, according to results of the Longitudinal Study of the Ocular Complications of AIDS.“With HIV and AIDS patients living longer than ever before, they are at an increased risk of developing several age-related diseases at an earlier age than HIV uninfected people including cardiovascular and diabetes,” Douglas A. Jabs, MD, MBA, said in a public release from the Mount Sinai Hospital/Mount Sinai School of Medicine, New York, (Read more...)

DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Robert Dempsey, vice president and head of Shire’s ophthalmic business unit, discusses the collaboration between the company and Foundation Fighting Blindness to treat rare diseases such as autosomal dominant retinitis pigmentosa.

Read more →

DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Dante J. Pieramici, MD, discusses research analyzing several anti-VEGF studies that show that the treatment may actually reverse the severity of diabetic retinopathy.

Read more →

DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Ben Yerxa, president of Envisia Therapeutics discusses the company’s research into drug delivery for glaucoma and retinal disease treatments.

Read more →

DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Michael J. Ellman, MD, discusses a long-term subgroup analysis from the RISE and RIDE trials showing an improvement in diabetic retinopathy grading from anti-VEGF treatment that may eliminate the need for pan-retinal photocoagulation laser treatment.

Read more →

DENVER — Intravitreal sirolimus does not seem to have any systemic adverse events in the treatment of noninfectious uveitis, according to a presentation here.In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Daniel Rosberger, MD, and colleagues observed the whole-blood pharmacokinetics of intravitreal sirolimus in 14 patients who took part in the double-masked phase of the SAKURA Study 1.

Read more →